Takeda in group trial for COVID-19 hyperimmune convalescent plasma treatment (NYSE:TAK)

Takeda (NYSE:TAK) is among a group of companies who have begun testing an experimental COVID-19 treatment derived from convalescent plasma of those recovered from the disease.

The study, funded by the National Institute of Allergy and Infectious Diseases, will compare the new drug in combination with Gilead Sciences’ (NASDAQ:GILD) antiviral remdesivir, vs. a treatment of remdesivir and a placebo.

The test concerns a drug – “hyperimmune intravenous immunoglobulin” (hIVIG) – combining antibodies taken from multiple recovered patients, in order to make a more potent and effective version of convalescent plasma therapy (usually dependent on antibodies derived from a single patient).

Several companies are collecting the antibodies for the drug; alongside Takeda, scientists from Emergent BioSolutions (NYSE:EBS), CSL Behring (OTCPK:CSLLY), and Grifols (NASDAQ:GRFS) are contributing. (Emergent announced its participation in the INSIGHT-013 hyperimmune study late on Thursday.)

The study could be completed by the end of this year or in early 2021, says CSL Behring’s Bill Mezzanotte, and if it shows a benefit, it could be used by multiple companies to seek approval for their hyperimmune products.

Takeda is up 1.2% Friday in Tokyo.

Source Article